LB-102 (methylated amisulpride) vs Lurasidone

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2/D3 receptor + 5-HT7 receptor · full Schizophrenia pipeline

LB-102 (methylated amisulpride)

Developed by LB Pharmaceuticals

Phase 3 in Schizophreniasmall molecule
Reliable signal

NCT06179108 · Phase 2 · completed

The trial randomized 359 participants to LB-102 or matched placebo and maintained quadruple masking of participants, clinicians, investigators, and outcome assessors. The primary clinical symptom endpoint, change in PANSS total score at Week 4, was significantly better with LB-102 than placebo for all three doses (50, 75, and 100 mg).

Next expected readout: June 2027 · NCT07363577 (registry estimate)

Reported efficacy

Change From Baseline to Week 4 in the PANSS Total Score (Baseline to Day 28 (4 weeks)): Change From Baseline to Week 4 in the PANSS Total Score (Baseline to Day 28 (4 weeks)): LB-102, 50 mg QD -14.28 score on a scale ± 1.097 vs LB-102, 75 mg QD -13.95 score on a scale ± 1.108 vs LB-102, 100 mg -16.08 score on a scale ± 1.906 vs Placebo Comparator -9.27 score on a scale ± 1.078; p=0.0009 (LB-102, 50 mg QD vs Placebo Comparator), p=0.0022 (LB-102, 75 mg QD vs Placebo Comparator), p=.0017 (LB-102, 100 mg vs Placebo Comparator) (met)

Result source: NCT06179108

Lurasidone

Marketed by Sumitomo Pharma and partners

Approved in Schizophreniasmall molecule
Reliable signal

NCT00549718 · Phase 3 · completed

The study randomized approximately 500 participants to lurasidone 40, 80, or 120 mg or placebo and used quadruple masking of participants, clinicians, investigators, and outcome assessors. Its clinical primary endpoint, change in total PANSS score over 6 weeks, favored lurasidone overall versus placebo and was statistically significant (p<0.05).

Reported efficacy

Mean change in Total PANSS Score From Baseline at Week 6: Change in PANSS total score at week 6 (prespecified primary analysis in the per-protocol set): -26.42±2.02 lurasidone vs -27.33±2.01 quetiapine XR (adjusted mean±SE); difference -0.91 (95% CI -6.35 to 4.53); lower limit above the -8.99 non-inferiority margin, met. The ITT set analysis also showed non-inferiority. (met)

Result source: NCT03465787

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLB-102 (methylated amisulpride)Lurasidone
PANSS total, change-14.3 vs -9.3−5 vs placebo50 mg QD · wk 4 · n 107NCT06179108
2 other results
  • -13.9 vs -9.3 75 mg QD · wk 4 · n 108 · Phase 2 · primary NCT06179108
  • -16.1 vs -9.3 100 mg · wk 4 · n 36 · Phase 2 · primary NCT06179108
-26.5 vs -10.3−16.2 vs placebo160 mg · wk 6 · n 121NCT00790192
24 other results
  • -19.2 vs -17 40mg · wk 6 · n 121 · Phase 3 · primary NCT00549718
  • -25.7 vs -16 40 mg · wk 6 · n 118 · Phase 3 · primary NCT00615433
  • -18.6 vs -10.5 40 mg · wk 6 · n 108 · Phase 3 · primary NCT01911429
  • -17.9 vs -13.1 40 mg · wk 6 · n 145 · Phase 3 · primary NCT01614899
  • -6.1 vs -2.5 40 mg · wk 6 · n 125 · Phase 3 · primary NCT00711269
  • -20.5 vs -17 120mg · wk 6 · n 123 · Phase 3 · primary NCT00549718
  • -23.6 vs -16 120 mg · wk 6 · n 118 · Phase 3 · primary NCT00615433
  • -23.4 vs -17 80mg · wk 6 · n 118 · Phase 3 · primary NCT00549718
  • -18.3 vs -10.5 80 mg · wk 6 · n 106 · Phase 3 · primary NCT01911429
  • -17.3 vs -13.1 80 mg · wk 6 · n 152 · Phase 3 · primary NCT01614899
  • -22.2 vs -10.3 80 mg · wk 6 · n 125 · Phase 3 · primary NCT00790192
  • -4.3 vs -2.5 80 mg · wk 6 · n 129 · Phase 3 · primary NCT00711269
  • -17.6 vs -14.5 20 mg · wk 6 · n 101 · Phase 3 · primary NCT01821378
  • -24.9 vs -14.5 80-160 mg · wk 6 · n 198 · Phase 3 · primary NCT01821378
  • -31.2 vs -34.9 wk 6 · n 194 · Phase 3 · primary NCT02002832
  • -21.7 vs -14.4 160 mg · wk 6 · n 43 · Phase 3 · secondary NCT01821378
  • -14.4 vs -14.4 80 mg · wk 6 · n 52 · Phase 3 · secondary NCT01821378
  • 8.3 vs 12.4 wk 28 · n 144 · Phase 3 · secondary NCT01435928
  • -34.6 vs -25.7 wk 52 · n 132 · Phase 3 · secondary NCT00789698
  • -14.1 vs -5.5 80 mg · wk 6 · n 90 · Phase 2 · secondary NCT00088634
  • -7.1 vs -12.3 wk 6 · n 71 · Phase 2 · secondary NCT00044044
  • -7.2 vs -12.3 wk 6 · n 65 · Phase 2 · secondary NCT00044044
  • -13.6 vs -12.3 wk 6 · n 70 · Phase 2 · secondary NCT00044044
  • -26.4 vs -27.3 wk 6 · Phase 3 · primary NCT03465787
CGI-S, change-0.7 vs -0.4−0.3 vs placebo50 mg QD · wk 4 · n 91NCT06179108
2 other results
  • -0.7 vs -0.4 75 mg QD · wk 4 · n 83 · Phase 2 · secondary NCT06179108
  • -0.8 vs -0.4 100 mg · wk 4 · n 23 · Phase 2 · secondary NCT06179108
-1.1 vs -1−0.1 vs placebo40mg · wk 6 · n 122NCT00549718
20 other results
  • -1.5 vs -1.1 40 mg · wk 6 · n 119 · Phase 3 · secondary NCT00615433
  • -1.0 vs -0.5 40 mg · wk 6 · n 108 · Phase 3 · secondary NCT01911429
  • -0.9 vs -0.8 40 mg · wk 6 · n 140 · Phase 3 · secondary NCT01614899
  • -1.3 vs -0.7 160 mg · wk 6 · n 43 · Phase 3 · secondary NCT01821378
  • -1.7 vs -0.9 160 mg · wk 6 · n 121 · Phase 3 · secondary NCT00790192
  • -1.2 vs -1 120mg · wk 6 · n 124 · Phase 3 · secondary NCT00549718
  • -1.4 vs -1.1 120 mg · wk 6 · n 118 · Phase 3 · secondary NCT00615433
  • -1.4 vs -1 80mg · wk 6 · n 119 · Phase 3 · secondary NCT00549718
  • -0.9 vs -0.5 80 mg · wk 6 · n 106 · Phase 3 · secondary NCT01911429
  • -1.0 vs -0.8 80 mg · wk 6 · n 150 · Phase 3 · secondary NCT01614899
  • -1.5 vs -0.9 80 mg · wk 6 · n 125 · Phase 3 · secondary NCT00790192
  • -0.9 vs -0.7 20 mg · wk 6 · n 101 · Phase 3 · secondary NCT01821378
  • -1.3 vs -0.7 80-160 mg · wk 6 · n 198 · Phase 3 · secondary NCT01821378
  • -0.8 vs -0.7 80 mg · wk 6 · n 52 · Phase 3 · secondary NCT01821378
  • 0.4 vs 0.7 wk 28 · n 144 · Phase 3 · secondary NCT01435928
  • -1.9 vs -1.6 wk 52 · n 132 · Phase 3 · secondary NCT00789698
  • -0.6 vs -0.2 80 mg · wk 6 · n 90 · Phase 2 · secondary NCT00088634
  • -0.5 vs -0.7 wk 6 · n 71 · Phase 2 · secondary NCT00044044
  • -0.4 vs -0.7 wk 6 · n 64 · Phase 2 · secondary NCT00044044
  • -0.8 vs -0.7 wk 6 · n 70 · Phase 2 · secondary NCT00044044
PANSS response—Trial running · NCT07363577—Not posted · NCT01143090
PSP, change—Trial running · NCT07363577—Not posted · NCT01143090
Relapse (% of patients)—Trial running · NCT0736357720.9% vs 26.6%vs Quetiapinewk 52 · n 139NCT00789698

PANSS total, change

LB-102 (methylated amisulpride)
-14.3 vs -9.3−5 vs placebo50 mg QD · wk 4 · n 107NCT06179108
2 other results
  • -13.9 vs -9.3 75 mg QD · wk 4 · n 108 · Phase 2 · primary NCT06179108
  • -16.1 vs -9.3 100 mg · wk 4 · n 36 · Phase 2 · primary NCT06179108
Lurasidone
-26.5 vs -10.3−16.2 vs placebo160 mg · wk 6 · n 121NCT00790192
24 other results
  • -19.2 vs -17 40mg · wk 6 · n 121 · Phase 3 · primary NCT00549718
  • -25.7 vs -16 40 mg · wk 6 · n 118 · Phase 3 · primary NCT00615433
  • -18.6 vs -10.5 40 mg · wk 6 · n 108 · Phase 3 · primary NCT01911429
  • -17.9 vs -13.1 40 mg · wk 6 · n 145 · Phase 3 · primary NCT01614899
  • -6.1 vs -2.5 40 mg · wk 6 · n 125 · Phase 3 · primary NCT00711269
  • -20.5 vs -17 120mg · wk 6 · n 123 · Phase 3 · primary NCT00549718
  • -23.6 vs -16 120 mg · wk 6 · n 118 · Phase 3 · primary NCT00615433
  • -23.4 vs -17 80mg · wk 6 · n 118 · Phase 3 · primary NCT00549718
  • -18.3 vs -10.5 80 mg · wk 6 · n 106 · Phase 3 · primary NCT01911429
  • -17.3 vs -13.1 80 mg · wk 6 · n 152 · Phase 3 · primary NCT01614899
  • -22.2 vs -10.3 80 mg · wk 6 · n 125 · Phase 3 · primary NCT00790192
  • -4.3 vs -2.5 80 mg · wk 6 · n 129 · Phase 3 · primary NCT00711269
  • -17.6 vs -14.5 20 mg · wk 6 · n 101 · Phase 3 · primary NCT01821378
  • -24.9 vs -14.5 80-160 mg · wk 6 · n 198 · Phase 3 · primary NCT01821378
  • -31.2 vs -34.9 wk 6 · n 194 · Phase 3 · primary NCT02002832
  • -21.7 vs -14.4 160 mg · wk 6 · n 43 · Phase 3 · secondary NCT01821378
  • -14.4 vs -14.4 80 mg · wk 6 · n 52 · Phase 3 · secondary NCT01821378
  • 8.3 vs 12.4 wk 28 · n 144 · Phase 3 · secondary NCT01435928
  • -34.6 vs -25.7 wk 52 · n 132 · Phase 3 · secondary NCT00789698
  • -14.1 vs -5.5 80 mg · wk 6 · n 90 · Phase 2 · secondary NCT00088634
  • -7.1 vs -12.3 wk 6 · n 71 · Phase 2 · secondary NCT00044044
  • -7.2 vs -12.3 wk 6 · n 65 · Phase 2 · secondary NCT00044044
  • -13.6 vs -12.3 wk 6 · n 70 · Phase 2 · secondary NCT00044044
  • -26.4 vs -27.3 wk 6 · Phase 3 · primary NCT03465787

CGI-S, change

LB-102 (methylated amisulpride)
-0.7 vs -0.4−0.3 vs placebo50 mg QD · wk 4 · n 91NCT06179108
2 other results
  • -0.7 vs -0.4 75 mg QD · wk 4 · n 83 · Phase 2 · secondary NCT06179108
  • -0.8 vs -0.4 100 mg · wk 4 · n 23 · Phase 2 · secondary NCT06179108
Lurasidone
-1.1 vs -1−0.1 vs placebo40mg · wk 6 · n 122NCT00549718
20 other results
  • -1.5 vs -1.1 40 mg · wk 6 · n 119 · Phase 3 · secondary NCT00615433
  • -1.0 vs -0.5 40 mg · wk 6 · n 108 · Phase 3 · secondary NCT01911429
  • -0.9 vs -0.8 40 mg · wk 6 · n 140 · Phase 3 · secondary NCT01614899
  • -1.3 vs -0.7 160 mg · wk 6 · n 43 · Phase 3 · secondary NCT01821378
  • -1.7 vs -0.9 160 mg · wk 6 · n 121 · Phase 3 · secondary NCT00790192
  • -1.2 vs -1 120mg · wk 6 · n 124 · Phase 3 · secondary NCT00549718
  • -1.4 vs -1.1 120 mg · wk 6 · n 118 · Phase 3 · secondary NCT00615433
  • -1.4 vs -1 80mg · wk 6 · n 119 · Phase 3 · secondary NCT00549718
  • -0.9 vs -0.5 80 mg · wk 6 · n 106 · Phase 3 · secondary NCT01911429
  • -1.0 vs -0.8 80 mg · wk 6 · n 150 · Phase 3 · secondary NCT01614899
  • -1.5 vs -0.9 80 mg · wk 6 · n 125 · Phase 3 · secondary NCT00790192
  • -0.9 vs -0.7 20 mg · wk 6 · n 101 · Phase 3 · secondary NCT01821378
  • -1.3 vs -0.7 80-160 mg · wk 6 · n 198 · Phase 3 · secondary NCT01821378
  • -0.8 vs -0.7 80 mg · wk 6 · n 52 · Phase 3 · secondary NCT01821378
  • 0.4 vs 0.7 wk 28 · n 144 · Phase 3 · secondary NCT01435928
  • -1.9 vs -1.6 wk 52 · n 132 · Phase 3 · secondary NCT00789698
  • -0.6 vs -0.2 80 mg · wk 6 · n 90 · Phase 2 · secondary NCT00088634
  • -0.5 vs -0.7 wk 6 · n 71 · Phase 2 · secondary NCT00044044
  • -0.4 vs -0.7 wk 6 · n 64 · Phase 2 · secondary NCT00044044
  • -0.8 vs -0.7 wk 6 · n 70 · Phase 2 · secondary NCT00044044

PANSS response

LB-102 (methylated amisulpride)
—Trial running · NCT07363577
Lurasidone
—Not posted · NCT01143090

PSP, change

LB-102 (methylated amisulpride)
—Trial running · NCT07363577
Lurasidone
—Not posted · NCT01143090

Relapse (% of patients)

LB-102 (methylated amisulpride)
—Trial running · NCT07363577
Lurasidone
20.9% vs 26.6%vs Quetiapinewk 52 · n 139NCT00789698
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. LB-102 (methylated amisulpride): 4 of 4 rows · Lurasidone: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLB-102 (methylated amisulpride)Lurasidone
Dropout rate
38.9%100 mg QDa
NCT06179108 · Phase 2
show 2 more results
29%50 mg QD
NCT06179108 · Phase 2
25.9%75 mg QD
NCT06179108 · Phase 2
32.8%40mga
NCT00549718 · Phase 3 · monotherapy
show 42 more results
31.5%120mg
NCT00549718 · Phase 3 · monotherapy
30.1%80mg
NCT00549718 · Phase 3 · monotherapy
35.8%40 mg
NCT00615433 · Phase 3 · monotherapy
44.5%120 mg
NCT00615433 · Phase 3 · monotherapy
0%Lurasidone
NCT02199743 · Phase 4 · registry result, not featured evidence
—Lurasidone (LUR)
NCT02199743 · Phase 4 · registry result, not featured evidence
33.3%
NCT01569659 · Phase 4 · registry result, not featured evidence
11.1%40 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
9.4%80 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
14.4%
NCT02002832 · Phase 3 · registry result, not featured evidence
44%40-mg or 80-mg
NCT01614912 · Phase 3 · registry result, not featured evidence
29.3%40 mg
NCT01614899 · Phase 3 · registry result, not featured evidence
25.2%80 mg
NCT01614899 · Phase 3 · registry result, not featured evidence
26.7%20 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
—80-160 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
75.3%
NCT01485640 · Phase 3 · registry result, not featured evidence
18.8%
NCT01566162 · Phase 3 · registry result, not featured evidence
—
NCT01435928 · Phase 3 · registry result, not featured evidence
41.8%160 mg
NCT00789698 · Phase 3 · registry result, not featured evidence
55.6%80 mg
NCT00789698 · Phase 3 · registry result, not featured evidence
21.6%40/40
NCT01143077 · Phase 3 · registry result, not featured evidence
17%40/80
NCT01143077 · Phase 3 · registry result, not featured evidence
18.3%80/80
NCT01143077 · Phase 3 · registry result, not featured evidence
65.6%
NCT00641745 · Phase 3 · registry result, not featured evidence
23.1%160 mg
NCT00790192 · Phase 3 · registry result, not featured evidence
28.8%80 mg
NCT00790192 · Phase 3 · registry result, not featured evidence
33.6%40 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
36.6%80 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
22.2%flexible dose
NCT01731119 · Phase 2 · registry result, not featured evidence
88.5%80 mg
NCT00088621 · Phase 2 · registry result, not featured evidence
42.2%80 mg
NCT00088634 · Phase 2 · registry result, not featured evidence
42.4%40 mg
NCT00044005 · Phase 2 · registry result, not featured evidence
66.7%80 mg
NCT00044005 · Phase 2 · registry result, not featured evidence
59.4%20 mg
NCT00044005 · Phase 2 · registry result, not featured evidence
62%20 mg
NCT00044044 · Phase 2 · registry result, not featured evidence
59.4%40 mg
NCT00044044 · Phase 2 · registry result, not featured evidence
56.3%80 mg
NCT00044044 · Phase 2 · registry result, not featured evidence
0%40 mg
NCT02174510 · Phase 1 · registry result, not featured evidence
0%80 mg
NCT02174510 · Phase 1 · registry result, not featured evidence
0%20 mg
NCT02174510 · Phase 1 · registry result, not featured evidence
10%40mg
NCT02174523 · Phase 1 · registry result, not featured evidence
14.3%
NCT01620060 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
8.3%100 mg QDa
NCT06179108 · Phase 2
show 2 more results
1.9%50 mg QD
NCT06179108 · Phase 2
2.8%75 mg QD
NCT06179108 · Phase 2
4.8%40mga
NCT00549718 · Phase 3 · monotherapy
show 42 more results
5.6%120mg
NCT00549718 · Phase 3 · monotherapy
6.5%80mg
NCT00549718 · Phase 3 · monotherapy
—40 mg
NCT00615433 · Phase 3 · monotherapy
—120 mg
NCT00615433 · Phase 3 · monotherapy
—Lurasidone
NCT02199743 · Phase 4 · registry result, not featured evidence
—Lurasidone (LUR)
NCT02199743 · Phase 4 · registry result, not featured evidence
—
NCT01569659 · Phase 4 · registry result, not featured evidence
4.6%40 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
2.8%80 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
—
NCT02002832 · Phase 3 · registry result, not featured evidence
—40-mg or 80-mg
NCT01614912 · Phase 3 · registry result, not featured evidence
—40 mg
NCT01614899 · Phase 3 · registry result, not featured evidence
—80 mg
NCT01614899 · Phase 3 · registry result, not featured evidence
—20 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
—80-160 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
6.2%
NCT01485640 · Phase 3 · registry result, not featured evidence
—
NCT01566162 · Phase 3 · registry result, not featured evidence
—
NCT01435928 · Phase 3 · registry result, not featured evidence
6.3%160 mg
NCT00789698 · Phase 3 · registry result, not featured evidence
6.9%80 mg
NCT00789698 · Phase 3 · registry result, not featured evidence
6.8%40/40
NCT01143077 · Phase 3 · registry result, not featured evidence
6.8%40/80
NCT01143077 · Phase 3 · registry result, not featured evidence
6.1%80/80
NCT01143077 · Phase 3 · registry result, not featured evidence
—
NCT00641745 · Phase 3 · registry result, not featured evidence
—160 mg
NCT00790192 · Phase 3 · registry result, not featured evidence
—80 mg
NCT00790192 · Phase 3 · registry result, not featured evidence
—40 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
—80 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
—flexible dose
NCT01731119 · Phase 2 · registry result, not featured evidence
—80 mg
NCT00088621 · Phase 2 · registry result, not featured evidence
—80 mg
NCT00088634 · Phase 2 · registry result, not featured evidence
—40 mg
NCT00044005 · Phase 2 · registry result, not featured evidence
—80 mg
NCT00044005 · Phase 2 · registry result, not featured evidence
—20 mg
NCT00044005 · Phase 2 · registry result, not featured evidence
—20 mg
NCT00044044 · Phase 2 · registry result, not featured evidence
—40 mg
NCT00044044 · Phase 2 · registry result, not featured evidence
—80 mg
NCT00044044 · Phase 2 · registry result, not featured evidence
—40 mg
NCT02174510 · Phase 1 · registry result, not featured evidence
—80 mg
NCT02174510 · Phase 1 · registry result, not featured evidence
—20 mg
NCT02174510 · Phase 1 · registry result, not featured evidence
—40mg
NCT02174523 · Phase 1 · registry result, not featured evidence
8.6%
NCT01620060 · Phase 1 · registry result, not featured evidence
Serious AEs
2.8%100 mg QDa
NCT06179108 · Phase 2
show 2 more results
0.9%50 mg QD
NCT06179108 · Phase 2
0.9%75 mg QD
NCT06179108 · Phase 2
1.6%40mga
NCT00549718 · Phase 3 · monotherapy
show 42 more results
4.8%120mg
NCT00549718 · Phase 3 · monotherapy
2.5%80mg
NCT00549718 · Phase 3 · monotherapy
1.7%40 mg
NCT00615433 · Phase 3 · monotherapy
5.1%120 mg
NCT00615433 · Phase 3 · monotherapy
—Lurasidone
NCT02199743 · Phase 4 · registry result, not featured evidence
7.1%Lurasidone (LUR)
NCT02199743 · Phase 4 · registry result, not featured evidence
3%
NCT01569659 · Phase 4 · registry result, not featured evidence
3.6%40 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
1.9%80 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
0.5%
NCT02002832 · Phase 3 · registry result, not featured evidence
11%40-mg or 80-mg
NCT01614912 · Phase 3 · registry result, not featured evidence
2.7%40 mg
NCT01614899 · Phase 3 · registry result, not featured evidence
1.9%80 mg
NCT01614899 · Phase 3 · registry result, not featured evidence
3%20 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
3%80-160 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
4.3%
NCT01485640 · Phase 3 · registry result, not featured evidence
6.8%
NCT01566162 · Phase 3 · registry result, not featured evidence
4.2%
NCT01435928 · Phase 3 · registry result, not featured evidence
7.6%160 mg
NCT00789698 · Phase 3 · registry result, not featured evidence
12.5%80 mg
NCT00789698 · Phase 3 · registry result, not featured evidence
4.2%40/40
NCT01143077 · Phase 3 · registry result, not featured evidence
2.3%40/80
NCT01143077 · Phase 3 · registry result, not featured evidence
0%80/80
NCT01143077 · Phase 3 · registry result, not featured evidence
11%
NCT00641745 · Phase 3 · registry result, not featured evidence
3.3%160 mg
NCT00790192 · Phase 3 · registry result, not featured evidence
0.8%80 mg
NCT00790192 · Phase 3 · registry result, not featured evidence
6.3%40 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
5.3%80 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
0%flexible dose
NCT01731119 · Phase 2 · registry result, not featured evidence
20.3%80 mg
NCT00088621 · Phase 2 · registry result, not featured evidence
2.2%80 mg
NCT00088634 · Phase 2 · registry result, not featured evidence
18.2%40 mg
NCT00044005 · Phase 2 · registry result, not featured evidence
9.1%80 mg
NCT00044005 · Phase 2 · registry result, not featured evidence
9.4%20 mg
NCT00044005 · Phase 2 · registry result, not featured evidence
5.6%20 mg
NCT00044044 · Phase 2 · registry result, not featured evidence
13.4%40 mg
NCT00044044 · Phase 2 · registry result, not featured evidence
4.2%80 mg
NCT00044044 · Phase 2 · registry result, not featured evidence
0%40 mg
NCT02174510 · Phase 1 · registry result, not featured evidence
0%80 mg
NCT02174510 · Phase 1 · registry result, not featured evidence
0%20 mg
NCT02174510 · Phase 1 · registry result, not featured evidence
0%40mg
NCT02174523 · Phase 1 · registry result, not featured evidence
1.9%
NCT01620060 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
100 mg QDa
insomnia 38.9% (placebo 22.2%)
agitation 11.1% (placebo 9.3%)
anxiety 11.1% (placebo 8.3%)
NCT06179108 · Phase 2
show 2 more results
50 mg QD
insomnia 25.2% (placebo 22.2%)
weight increased 12.1% (placebo 3.7%)
headache 11.2% (placebo 9.3%)
NCT06179108 · Phase 2
75 mg QD
insomnia 21.3% (placebo 22.2%)
anxiety 8.3% (placebo 8.3%)
headache 8.3% (placebo 9.3%)
NCT06179108 · Phase 2
40mga
headache 18.5% (placebo 15.7%)
akathisia 11.3% (placebo 51.2%)
nausea 11.3% (placebo 7.1%)
NCT00549718 · Phase 3 · monotherapy
show 41 more results
120mg
akathisia 24.2% (placebo 51.2%)
headache 16.9% (placebo 15.7%)
somnolence 14.5% (placebo 5.5%)
NCT00549718 · Phase 3 · monotherapy
80mg
akathisia 17.4% (placebo 51.2%)
headache 13.2% (placebo 15.7%)
sedation 10.7% (placebo 4.7%)
NCT00549718 · Phase 3 · monotherapy
40 mg
headache 21.8% (placebo 21.6%)
insomnia 12.6% (placebo 11.2%)
akathisia 11.8% (placebo 0.9%)
NCT00615433 · Phase 3 · monotherapy
120 mg
akathisia 22.9% (placebo 0.9%)
headache 17.8% (placebo 21.6%)
somnolence 15.3% (placebo 4.3%)
NCT00615433 · Phase 3 · monotherapy
insomnia 21.4%
sedation 21.4%
stiffness in jaw 14.3%
NCT02199743 · Phase 4 · registry result, not featured evidence
nausea 27.3%
headache 15.2%
insomnia 12.1%
NCT01569659 · Phase 4 · registry result, not featured evidence
40 mg
nausea 12.7% (placebo 2.7%)
anxiety 10% (placebo 8%)
akathisia 9.1% (placebo 1.8%)
NCT01911429 · Phase 3 · registry result, not featured evidence
80 mg
nausea 14.4% (placebo 2.7%)
somnolence 11.5% (placebo 5.4%)
headache 10.6% (placebo 12.5%)
NCT01911429 · Phase 3 · registry result, not featured evidence
extrapyramidal disorder 17%
consitpation 12.9%
insomnia 9.8%
NCT02002832 · Phase 3 · registry result, not featured evidence
40-mg or 80-mg
insomnia 11.3%
akathisia 11%
nasopharyngitis 10.6%
NCT01614912 · Phase 3 · registry result, not featured evidence
40 mg
headache 9.3% (placebo 7.9%)
constipation 8.7% (placebo 7.9%)
akathisia 7.3% (placebo 3.3%)
NCT01614899 · Phase 3 · registry result, not featured evidence
80 mg
akathisia 10.4% (placebo 3.3%)
nausea 7.8% (placebo 4.6%)
anxiety 7.1% (placebo 5.3%)
NCT01614899 · Phase 3 · registry result, not featured evidence
20 mg
insomnia 15.8% (placebo 21.4%)
headache 9.9% (placebo 7.1%)
anxiety 7.9% (placebo 6.3%)
NCT01821378 · Phase 3 · registry result, not featured evidence
80-160 mg
akathisia 10.6% (placebo 1.8%)
insomnia 10.6% (placebo 21.4%)
nausea 8.6% (placebo 3.6%)
NCT01821378 · Phase 3 · registry result, not featured evidence
headache 5.6%
diarrhoea 3.7%
influenza 3.7%
NCT01485640 · Phase 3 · registry result, not featured evidence
akathisia 5.2%
schizophrenia 4.2%
nasopharyngitis 2.6%
NCT01566162 · Phase 3 · registry result, not featured evidence
schizophrenia 6.9% (placebo 7.8%)
insomnia 6.3% (placebo 7.1%)
anxiety 4.2% (placebo 2.8%)
NCT01435928 · Phase 3 · registry result, not featured evidence
160 mg
headache 13.9%
akathisia 10.1%
insomnia 8.9%
NCT00789698 · Phase 3 · registry result, not featured evidence
80 mg
akathisia 15.3%
headache 6.9%
insomnia 6.9%
NCT00789698 · Phase 3 · registry result, not featured evidence
40/40
nausea 13.9%
headache 9.7%
somnolence 9.7%
NCT01143077 · Phase 3 · registry result, not featured evidence
40/80
insomnia 18.4%
akathisia 14.9%
headache 11.5%
NCT01143077 · Phase 3 · registry result, not featured evidence
80/80
nausea 18.5%
insomnia 14.8%
akathisia 13.6%
NCT01143077 · Phase 3 · registry result, not featured evidence
nausea 16.7%
insomnia 15.8%
sedation 14.6%
NCT00641745 · Phase 3 · registry result, not featured evidence
160 mg
headache 9.9% (placebo 10.7%)
akathisia 7.4% (placebo 0.8%)
vomiting 7.4% (placebo 5%)
NCT00790192 · Phase 3 · registry result, not featured evidence
80 mg
insomnia 11.2% (placebo 9.1%)
headache 9.6% (placebo 10.7%)
akathisia 8% (placebo 0.8%)
NCT00790192 · Phase 3 · registry result, not featured evidence
40 mg
insomnia 14.2% (placebo 14.4%)
schizophrenia 11.8% (placebo 18.9%)
nasopharyngitis 10.2% (placebo 9.8%)
NCT00711269 · Phase 3 · registry result, not featured evidence
80 mg
insomnia 19.1% (placebo 14.4%)
schizophrenia 19.1% (placebo 18.9%)
akathisia 11.5% (placebo 4.5%)
NCT00711269 · Phase 3 · registry result, not featured evidence
flexible dose
nausea 33.3%
NCT01731119 · Phase 2 · registry result, not featured evidence
80 mg
bronchitis 6.8%
nausea 6.8%
sedation 6.8%
NCT00088621 · Phase 2 · registry result, not featured evidence
80 mg
nausea 16.7% (placebo 3.3%)
constipation 11.1% (placebo 5.6%)
headache 11.1% (placebo 10%)
NCT00088634 · Phase 2 · registry result, not featured evidence
40 mg
dizziness 18.2%
headache 15.2%
nasopharyngitis 12.1%
NCT00044005 · Phase 2 · registry result, not featured evidence
80 mg
headache 15.2%
depression 12.1%
oropharyngeal pain 9.1%
NCT00044005 · Phase 2 · registry result, not featured evidence
20 mg
headache 15.6%
insomnia 9.4%
nasopharyngitis 9.4%
NCT00044005 · Phase 2 · registry result, not featured evidence
headache 21.1% (placebo 33.3%)
dyspepsia 11.3% (placebo 9.7%)
nausea 11.3% (placebo 11.1%)
NCT00044044 · Phase 2 · registry result, not featured evidence
headache 23.9% (placebo 33.3%)
sedation 16.4% (placebo 8.3%)
agitation 13.4% (placebo 4.2%)
NCT00044044 · Phase 2 · registry result, not featured evidence
headache 23.9% (placebo 33.3%)
sedation 21.1% (placebo 8.3%)
akathisia 18.3% (placebo 9.7%)
NCT00044044 · Phase 2 · registry result, not featured evidence
40 mg
somnolence 75% (placebo 33.3%)
blood prolactin increased 12.5% (placebo 22.2%)
irritability 12.5% (placebo 0%)
NCT02174510 · Phase 1 · registry result, not featured evidence
80 mg
somnolence 100% (placebo 33.3%)
blood prolactin increased 83.3% (placebo 22.2%)
dizziness 25% (placebo 0%)
NCT02174510 · Phase 1 · registry result, not featured evidence
20 mg
somnolence 62.5% (placebo 33.3%)
blood prolactin increased 12.5% (placebo 22.2%)
feeling hot 12.5% (placebo 0%)
NCT02174510 · Phase 1 · registry result, not featured evidence
40mg
somnolence 100% (placebo 0%)
blood prolactin increased 60% (placebo 25%)
restlessness 60% (placebo 0%)
NCT02174523 · Phase 1 · registry result, not featured evidence
somnelence 41.9%
sedation 18.1%
nausea 17.1%
NCT01620060 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Lurasidone

BACS Composite -2.002433521 score @ 4wk
absolute change · score
No placebo or comparator arm
NCT02199743 · Phase 4 · registry result, not featured evidence
PANSS Positive Subscale 24.2 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT01569659 · Phase 4 · registry result, not featured evidence
PANSS Positive -6.3 vs -3.1 placebo score @ 6wk40 mg
absolute change · score
NCT01911429 · Phase 3 · registry result, not featured evidence
show 3 more results
-2 vs -0.6 placebo score @ 6wk40 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
-6.3 vs -3.1 placebo score @ 6wk80 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
-1.4 vs -0.6 placebo score @ 6wk80 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
PANSS 20 63.9% (n=108) vs 61.6% (n=112) placebo @ 6wk40 mg
responder rate · % of participants
NCT01911429 · Phase 3 · registry result, not featured evidence · converted to % from 69 number of participants as posted
show 3 more results
44.3% (n=106) vs 61.6% (n=112) placebo @ 6wk*80 mg
NCT01911429 · Phase 3 · registry result, not featured evidence · converted to % from 47 number of participants as posted
44% (n=101) vs 73% (n=112) placebo @ 6wk20 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
53% (n=198) vs 73% (n=112) placebo @ 6wk80-160 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
PQLES Total 5.6 vs 0.3 placebo score @ 6wk40 mg
absolute change · score
NCT01911429 · Phase 3 · registry result, not featured evidence
show 1 more result
6.1 vs 0.3 placebo score @ 6wk80 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
CGAS 11.3 vs 7.5 placebo score @ 6wk40 mg
absolute change · score
NCT01911429 · Phase 3 · registry result, not featured evidence
show 1 more result
11.9 vs 7.5 placebo score @ 6wk80 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
PANSS General Psychopathology -8.1 vs -5.3 placebo score @ 6wk40 mg
absolute change · score
NCT01911429 · Phase 3 · registry result, not featured evidence
show 5 more results
-8.8 vs -6.3 placebo score @ 6wk40 mg
NCT01614899 · Phase 3 · registry result, not featured evidence
-2.4 vs -1 placebo score @ 6wk40 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
-8.1 vs -5.3 placebo score @ 6wk80 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
-7.9 vs -6.3 placebo score @ 6wk80 mg
NCT01614899 · Phase 3 · registry result, not featured evidence
-1.2 vs -1 placebo score @ 6wk80 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
PANSS Marder Uncontrolled Hostility/Excitement -0.6 vs -2.4 placebo score @ 6wk40 mg
absolute change · score
NCT01911429 · Phase 3 · registry result, not featured evidence
show 1 more result
-1.7 vs -2.4 placebo score @ 6wk80 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
CGI-I 2 vs 1.9 Risperidone score @ 6wk
absolute value · score
NCT02002832 · Phase 3 · registry result, not featured evidence
PANSS Total -28.4 score @ 32wk40-mg or 80-mg
absolute change · score
Extension (open-label)
No placebo or comparator arm
NCT01614912 · Phase 3 · registry result, not featured evidence
show 1 more result
-8.4 score @ 12wk
NCT01566162 · Phase 3 · registry result, not featured evidence
CGI-S -1.46 score @ 32wk40-mg or 80-mg
absolute change · score
Extension (open-label)
No placebo or comparator arm
NCT01614912 · Phase 3 · registry result, not featured evidence
show 1 more result
-0.48 score @ 12wk
NCT01566162 · Phase 3 · registry result, not featured evidence
PANSS Positive Subscale -8.4 score @ 32wk40-mg or 80-mg
absolute change · score
Extension (open-label)
No placebo or comparator arm
NCT01614912 · Phase 3 · registry result, not featured evidence

+ 18 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: LB-102 (methylated amisulpride)'s landscape · Lurasidone's landscape